NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte.

Udden, Sm Nashir; Kwak, Youn-Tae; Godfrey, Victoria; Khan, Md Abdul Wadud; Khan, Shahanshah; Loof, Nicolas; Peng, Lan; Zhu, Hao et al. · Elife · 2019

basic_science · Level V

Where this comes from

Abstract

Hepatocellular carcinoma (HCC) is a deadly human cancer associated with chronic inflammation. The cytosolic pathogen sensor NLRP12 has emerged as a negative regulator of inflammation, but its role in HCC is unknown. Here we investigated the role of NLRP12 in HCC using mouse models of HCC induced by carcinogen diethylnitrosamine (DEN). <i>Nlrp12<sup>-/-</sup></i> mice were highly susceptible to DEN-induced HCC with increased inflammation, hepatocyte proliferation, and tumor burden. Consistently, <i>Nlrp12<sup>-/-</sup></i> tumors showed higher expression of proto-oncogenes cJun and cMyc and downregulation of tumor suppressor p21. Interestingly, antibiotics treatment dramatically diminished tumorigenesis in <i>Nlrp12<sup>-/-</sup></i> mouse livers. Signaling analyses demonstrated higher JNK activation in <i>Nlrp12<sup>-/-</sup></i> HCC and cultured hepatocytes during stimulation with microbial pattern molecules. JNK inhibition or NLRP12 overexpression reduced proliferative and inflammatory responses of <i>Nlrp12<sup>-/-</sup></i> hepatocytes. In summary, NLRP12 negatively regulates HCC pathogenesis via downregulation of JNK-dependent inflammation and proliferation of hepatocytes.

Medical subject headings